PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy. (Q50421758)

http://europepmc.org/abstract/MED/29484451

13 March 2018

title

PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6716527&resulttype=core&format=json

12 May 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6716527&resulttype=core&format=json

12 May 2020

Jaroslaw Cwikla

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6716527&resulttype=core&format=json

12 May 2020

author name string

Lisa Bodei

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6716527&resulttype=core&format=json

12 May 2020

Mark S Kidd

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6716527&resulttype=core&format=json

12 May 2020

Aviral Singh

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6716527&resulttype=core&format=json

12 May 2020

Wouter A van der Zwan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6716527&resulttype=core&format=json

12 May 2020

Stefano Severi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6716527&resulttype=core&format=json

12 May 2020

Richard P Baum

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6716527&resulttype=core&format=json

12 May 2020

Dik J Kwekkeboom

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6716527&resulttype=core&format=json

12 May 2020

Giovanni Paganelli

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6716527&resulttype=core&format=json

12 May 2020

Eric P Krenning

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6716527&resulttype=core&format=json

12 May 2020

Irvin M Modlin

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6716527&resulttype=core&format=json

12 May 2020

publication date

26 February 2018

1 reference

http://europepmc.org/abstract/MED/29484451

13 March 2018

number of pages

15

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6716527&resulttype=core&format=json

12 May 2020

volume

45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6716527&resulttype=core&format=json

12 May 2020

page(s)

1155-1169

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6716527&resulttype=core&format=json

12 May 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6716527&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00259-018-3967-6

12 May 2020

exact match

0 references

cites work

Clinical biomarkers in drug discovery and development

1 reference

12 December 2020

Gastroenteropancreatic neuroendocrine tumours

1 reference

12 December 2020

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

12 December 2020

68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy

1 reference

12 December 2020

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

1 reference

12 December 2020

68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors.

1 reference

12 December 2020

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

1 reference

12 December 2020

Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification

1 reference

12 December 2020

Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate

1 reference

12 December 2020

Decreased expression of genes involved in oxidative phosphorylation in human pancreatic islets from patients with type 2 diabetes

1 reference

12 December 2020

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study

1 reference

12 December 2020

Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors

1 reference

12 December 2020

Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC?

1 reference

12 December 2020

A blood-based proteomic classifier for the molecular characterization of pulmonary nodules.

1 reference

12 December 2020

Gastroenteropancreatic neuroendocrine neoplasms: historical context and current issues

1 reference

12 December 2020

Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis.

1 reference

12 December 2020

Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.

1 reference

12 December 2020

Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours

1 reference

12 December 2020

Relevance of PET for pretherapeutic prediction of doses in peptide receptor radionuclide therapy

1 reference

12 December 2020

Validation of a multiprotein plasma classifier to identify benign lung nodules

1 reference

12 December 2020

Hypoxia induces a lipogenic cancer cell phenotype via HIF1α-dependent and -independent pathways

1 reference

12 December 2020

Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine

1 reference

12 December 2020

Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status

1 reference

12 December 2020

Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.

1 reference

12 December 2020

Biomarker: Predictive or Prognostic?

1 reference

12 December 2020

Long-term results of PRRT in advanced bronchopulmonary carcinoid

1 reference

12 December 2020

Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.

1 reference

12 December 2020

Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests

1 reference

12 December 2020

Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor

1 reference

12 December 2020

Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer

1 reference

12 December 2020

The changing paradigm of tumour response to irradiation

1 reference

12 December 2020

A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management

1 reference

12 December 2020

Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.

1 reference

12 December 2020

Transcriptome and Proteome Analyses of TNFAIP8 Knockdown Cancer Cells Reveal New Insights into Molecular Determinants of Cell Survival and Tumor Progression

1 reference

12 December 2020

An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies

1 reference

12 December 2020

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

1 reference

12 December 2020

Radionuclide Therapy for Neuroendocrine Tumors

1 reference

12 December 2020

Therapy: The role of liquid biopsies to manage and predict PRRT for NETs.

1 reference

12 December 2020

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents.

1 reference

12 December 2020

Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.

1 reference

12 December 2020

The safety of available treatments options for neuroendocrine tumors

1 reference

12 December 2020

10.1007/S00259-018-3967-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6716527&resulttype=core&format=json

12 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6716527&resulttype=core&format=json

12 May 2020

1 reference